PerkinElmer Immunoassay helps to disrupt the SARS-CoV-2 Spike Protein/ACE2 Interaction
Singapore, Oct. 22 -- PerkinElmer, Inc. on 21 Oct 2020 announced that a research team at the National Center for Advancing Translational Sciences (NCATS), an arm of the National Institutes of Health (NIH), is working with PerkinElmer's AlphaLISA(R) immunoassay to help support the global search for effective COVID-19 therapeutics.
The NCATS research project is focused on studying small molecule drug compounds that are already approved and in use as treatments but could potentially be repurposed for COVID-19.
The goal of the project is to quickly and reliably identify which small molecule compounds can best disrupt key proteins that bind together to allow for SARS-CoV-2 infection -- the S1 spike protein and the host ACE2 receptor.
Using ...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.